HC Wainwright Reiterates Rating on Damora Therapeutics, Inc. $DMRA
Key Points
- HC Wainwright now rates Damora Therapeutics, Inc. ($DMRA) "buy" with a $45.00 target.
- The Street's average $DMRA price target is $43.38 (Strong Buy).
- $DMRA last traded around $21.38.
HC Wainwright reiterated its rating on Damora Therapeutics, Inc. ($DMRA) to a "buy" rating, with a price target of $45.00 in a recent research note.
Damora Therapeutics, Inc. ($DMRA) Stock
Damora Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.